BioMarin Pharmaceutical Inc.
105 Digital Drive
Novato
California
94949
U.S.A.
Phone:
415-506-6700
Fax:
415-382-7427
|
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), and Kuvan® (sapropterin dihydrochloride) for the treatment of phenylketonuria (PKU).
For additional information, please visit www.BMRN.com.
Management Team:
Jean-Jacques Bienaimé, Chief Executive Officer
Jeffrey H. Cooper, Senior Vice President, Chief Financial Officer
Henry J. Fuchs, M.D., Senior Vice President, Chief Medical Officer
Stephen Aselage, Senior Vice President, Global Commercial Operations
Robert A. Baffi, Ph.D., Senior Vice President, Technical Operations
G. Eric Davis, Vice President, Corporate Counsel & Secretary
Mark Wood, Vice President, Human Resources
Amy Waterhouse, Vice President, Regulatory & Government Affairs
Board of Directors:
Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin
Michael Grey, President and CEO, Auspex Pharmaceuticals, Inc.
Elaine Heron, Ph.D. Chairman and CEO, Amplyx Pharmaceuticals, Inc.
Joseph Klein III, Managing Director, Gauss Capital Advisors, LLC.
Pierre Lapalme, Former President and CEO, North American Ethypharm Inc.
V. Bryan Lawlis, Ph.D., President and CEO, Itero Biopharmaceuticals, Inc.
Alan J. Lewis, Ph.D., President and CEO, Juvenile Diabetes Research Foundation
Randy Meier, President and COO, Advanced Medical Optics, Inc.
Email:
ir@bmrn.com
Ownership:
Web Site:
BioMarin Pharmaceutical Inc.
Employees:
358
Symbol: BMRN
|